

International Medical Events I.M.E, la marque P.C.O du Groupe Equatour

38 rue de Laborde - 75008 Paris Tel.: 00 33 (0)1 41 04 04 04 Fax: 00 33 (0) 1 41 04 04 11

Join us on Linked in



Dear Friends,

We are pleased and honored to report that the Fifth Edition of IFODS will be held in Paris from 22-24 June, 2022. The Fourth Edition has faced an important success, with over 577 participants (307 in attendance and 270 in virtual). The quality talks and sessions have received such positive feedback across the board that we have decided to go ahead with our plans to create a major national oncology conference, in close collaboration with national oncology societies and leading international experts. Regarding the setting of International meetings in 2022 and according to the current sanitary crisis, we have decided to plan our next meeting in June.

Meanwhile, we must continue to promote this conference to grow attendance year after year and to provide sustained excellence in oncology training. This is why we are moving the event to a more central and accessible location in Paris. This venue is even more conducive to dialogue and communication, everything being on the same floor where partners and attendees can interact, the meeting rooms all around, or the auditorium for plenary sessions.

We are looking forward to welcoming you at the Rive Montparnasse business center, which is very close to Montparnasse train station.

As in previous editions, the French Cancer Society (SFC) is working alongside IFODS to organize a special opening session on the Future of Oncology, with contributions from scientists and young oncologists. Institution like EACR is also expected to provide renewed support.

IFODS seeks to promote the efforts of all who fight against cancer, by sharing the best and latest developments in oncology as well as best practice guidelines. In line with this objective, IFODS is delighted to welcome Biotech Societies and also patients and patient groups to its Science Committee meetings and to a number of sessions. The conference will provide these honored guests with opportunities to learn about therapeutic approaches and to confer with healthcare providers.

France is a key player within the global field of oncology and, as such, deserves a world-leading conference on a par with its excellent level of care.

Please join us in Paris from 22-24 June, 2022, for the Fifth Edition of IFODS. As always, pride of place will go to training, dialogue, sharing and excellence in science, in a warm and friendly environment. Thank you in advance for your support and participation.

We hope to see you there!

We wish you to all of you an Healthy and Happy New Year

With kind regards,

Jean-Philippe SPANO
President of the IFODS Science Committee

PROGRAM

	•	ROOKAM	
WEDNESDAY 22 ND JUNE	LA SEINE PLENARY ROOM	MISSISSIPI ROOM	ST LAURENT ROOM
MORNING	10:00-10:30 AM WELCOMING SESSION Jean-Philippe SPANO 10:30-12:30 AM CONSENSUS AND GUIDELINES FOR LUNG CANCER (1) Under the auspices of our respective groups: IFCT, Oncology Group/SPLF With the Support of JANSSEN	10:30 AM-12:30 PM PRECISION MEDICINE IN GYNECOLOGIC AND PROSTATE CANCER Under the aegis of SFMPP With the Support of GSK	11:30-12:30 AM SESSION GEMO " GROUPE EUROPÉEN D'ETUDE DES MÉTASTASES OSSEUSES Sous l'égide du groupe GEMO
AFTERNOON	02:00-04:45 PM CONSENSUS AND GUIDELINES FOR LUNG CANCER (2) Under the auspices of our respective groups: IFCT, Oncology Group/SPLF 04:45-05:15 PM AWARD CEREMONY	02:00-04:45 PM OPENING SESSION: THE FUTURE OF ONCOLOGY (Basic Science) Under the aegis of SFC	02:00-04:45 PM CONTINUING EDUCATION Under the aegis of S0F0M & AERIO
	CLAUDE JACQUILLAT		
THURSDAY 23 RD JUNE	LA SEINE PLENARY ROOM	MISSISSIPI ROOM	ST LAURENT ROOM
MORNING	09:00-12:30 PM CONSENSUS AND GUIDELINES FOR BREAST CANCER (1) Under the aegis of ST PAUL & AROME	09:00-12:30 PM BIOTECH IN ONCOLOGY Under the aegis of Gustave Roussy Transfert, Cancer Campus and Angels Santé	09:00-12:30 PM CONSENSUS AND GUIDELINES FOR UROLOGY: PROSTATE CANCER CARE Under the aegis of AFU With the Support of ASTELLAS
	12:30-1:30 PM LUNCH-DEBATE ROUND TABLE: PARADIGM SHIFT IN THE MANAGEMENT OF BREAST CANCER? With the Support of ASTRAZENECA/ DAIICHI SANKYO	12:30-1:30 PM SYMPOSIUM IMMUNOTHERAPY IN PAN-TUMOR NEWS IN LOCALLY ADVANCED/METASTATIC SITUATIONS With the Support of BMS	12:30-1:30 PM LUNCH-DEBATE With the Support of MYRIAD GENETICS
AFTERNOON	02:00-02:30 PM LA LEÇON DES IFODS THERAPEUTICAL INNOVATIONS: WHERE? FOR WHOM AND HOW?	02:30-04:15 PM CONSENSUS AND GUIDELINES FOR ONCO DERMATOLOGY	02:30-04:45 PM INNOVATIONS IN RADIOTHERAPY Under the aegis of SFRO & SFJRO
	02:30-04:30 PM CONSENSUS AND GUIDELINES FOR BREAST CANCER (2) Under the aegis of ST PAUL & AROME With the Support of MSD & GILEAD	04:15-05:15 PM GYNECOLOGICAL CANCERS: "HIGHLIGHTS FROM THE SGO AND ASCO Under the aegis of SFCO, GINECO GROUP & SFMPP	
	04:30-05:30 PM SYMPOSIUM MANAGEMENT OF METASTATIC BREAST CANCER RH+ HER2- With the Support of NOVARTIS		
FRIDAY 24 TH June	LA SEINE PLENARY ROOM	MISSISSIPI ROOM	ST LAURENT ROOM
MORNING -	09:00 AM-12.30 PM HIGHLIGHTS FITI* SESSION 2022 A Major Oncology Year With the Support of PFIZER & STEMLINE MENARINI	09:00-12:30 AM CONSENSUS AND GUIDELINES FOR GI TUMORS Under the aegis of Prodige Group, UNICANCER GI, GERCOR, FFCD With the Support of MSD	09:00-10:30 AM CANCER, APRÈS-CANCER, RESSOURCES ET RÉSILIENCE Sous l'égide d'Europa Donna, Life is Rose, L'UDP, Patients en réseau With the Support of L'OREAL FONDATION
	12:30-1:30 PM LUNCH-DEBATE EUROPEAN GUIDELINES FOR BREAST CANCER Under the aegis of ST PAUL & AROME With the Support of SEAGEN		11:00-12:30 AM CONSENSUS AND GUIDELINES FOR SARCOMA Under the aegis of GSF-GETO & NET-SARC
AFTERNOON			02:00-03:30 PM HEART VESSELS AND CANCERS NEW EXPERT OPINION With the Support of LEO PHARMA
			03:30-04:00 PM POSTERS AWARD



SCIENTIFIC SYMPOSIUM ON PROGRAM

Scientific Symposia are sessions during which some of the world best experts will, upon invitation, address different issues related to a specific topic. Each scientific symposium will end with a round table discussion and Q & A with the audience.

WEDNESDAY 22nd JUNE

10:00-10:30 AM

▶PLENARY ROOMWELCOMING SESSION: Jean-Philippe SPANO

LA SEINE (PLENARY)

10:30-12:30 AM

▶CONSENSUS AND GUIDELINES FOR LUNG CANCER (1)

Under the auspices of our respective groups: IFCT, Oncology Group/SPLF

With the Support of JANSSEN

Presidents: Virginie Westeel, Frances Shepherd

Chairpersons: Agathe Seguin-Givelet, Sébastien Thureau, Marie Wislez

STAGE I-III NSCLC

10:30 AM: Infralobar resections. Agathe Seguin-Givelet

11:00 AM: Update on perioperative immunotherapy. Marie Wislez

11:30 AM: Update on Post-operative Treatment of Resected EGFR NSCLC. Frances Shepherd

11:40 AM: Ongoing studies of radiotherapy and perspectives. Etienne Martin

≥12:30-2:00 PM

LUNCH BOX

02:00-04:45 PM

▶CONSENSUS AND GUIDELINES FOR LUNG CANCER (2)

Under the auspices of our respective groups: IFCT, Oncology Group/SPLF

Presidents: Elisabeth Quoix, Frances Shepherd

STAGE IV NSCLC AND OTHER CANCERS

Chairpersons: Françoise Mornex, Diane Damotte

02:00 PM: Oligometastatic disease: concept, therapeutic challenges and strategies.

Ania Wrona, Françoise Mornex

02:30 PM: When should immunotherapy be stopped in responders? Céline Mascaux 03:00 PM: New antibodies: clinical context, efficacy and safety. Maurice Perol 🚇

03:30-03:45 PM: pause / visite sur les stands / break

03:45 PM: Malignant pleural mesothelioma. Arnaud Scherpereel

04:15 PM: Thymic epithelial tumours. Nicolas Girard



WEDNESDAY 22nd JUNE

LA SEINE (PLENARY)

04:45-05:15 PM

PAWARD CEREMONY

CLAUDE JACQUILLAT

MISSISSIPI

10:30 AM-12:30 PM

▶PRECISION MEDICINE IN GYNECOLOGIC AND PROSTATE CANCER

Under the aegis of SFMPP

President: Pascal Pujol

PARP inhibtors in prostate cancer. Pierre Mongiat-Artus
 With the Support of GSK

- · Immunotherapy in gynecologic cancer: state of the art. Alexandra Leary
- European consensus on HRD in ovarian cancer. Diether Lambrechts
- Development of HRD solutions. Pascal Pujol

≥12:30-2:00 PM

· LUNCH BOX

02:00-04:45 PM

▶Opening Session: THE FUTURE OF ONCOLOGY (Basic Science)

Under the aegis of SFC

Presidents and Chairpersons: Manuel Rodrigues, Jacques-Olivier Bay, Jean-Pierre Armand and Jacques Robert

Introduction: Jean-Philippe Spano, Jacques Robert

- 02:30-03:00 PM: Management of breast cancer from Halsted to personalised medicine: what to expect tomorrow? Jean-Yves Pierga, (Medical oncologist, Institut Curie, Paris)
- 03:00-03:30 PM: Radiotherapy in 2030. Laurent Quero, (Oncologist Radiotherapist, Hôpital St Louis, Paris)

03:30-03:45 PM: pause / visite sur les stands / break

- 03:45-04:15 PM: Supportive care in 2030. Carole Bouleuc, (Head of the Support Care Department, Institut Curie, Paris)
- 04:15-04:45 PM: Tomorrow, the advent of preventive precision medicine. Pierre Saintigny, (Medical oncologist at the Léon Bérard Centre and Team Leader at the Lyon Cancer Research Centre)

ST LAURENT

11:30-12:30 AM

▶SESSION GEMO " GROUPE EUROPÉEN D'ETUDE DES MÉTASTASES OSSEUSES"

Sous l'égide du groupe GEMO

Presidents and Chairpersons: Marie-Hélène Vieillard, Frédéric Clarençon and Laetitia Morardet

How to limit bone complications in patients with prostate and breast cancer.
 Françoise Debiais



WEDNESDAY 22nd JUNE

ST LAURENT

02:00-04:45 PM

CONTINUING EDUCATION

Under the aegis of SOFOM & AERIO

Presidents: Joseph Gligorov, Stéphane Culine, Matthieu Delaye & Christophe Tournigand

ONCO NEPHROLOGY

Chairpersons: Dil Sahali, Christophe Tournigand

- 02:00-02:30 PM: Renal complications of immunotherapy. Julie Belliere
- 02:30-03:00 PM: Nephrological management in Cancer patients. Corinne Isnard Bagnis
- 03:00-03:30 PM: Oncological management in renal transplant patients. Christophe Tournigand

03:30-03:45 PM: pause / visite sur les stands / break

INITIAL AND CONTINUING TRAINING IN MEDICAL ONCOLOGY

- 03:45-04:15 PM: Access of oncology interns to scientific publications. Marc Hilmi
- 04:15-04:45 PM: Towards a certification program in medical oncology. Adrien Rousseau

>POSTERS SESSION (on the Exhibition area)



LA SEINE (PLENARY)

09:00-12:30 AM

▶ CONSENSUS AND GUIDELINES FOR BREAST CANCER (1)

Under the aegis of St Paul & AROME

Presidents: Moïse Namer, Marc Spielmann, Yazid Belkacemi, Joseph Gligorov What did we identify as therapeutic issues during the Nice-St Paul 2022 courses?

- 09:00-09:45 AM: THE CHALLENGES OF BREAST CANCER SURGERY IN 2022 ROUND TABLE MODERATED BY Catherine Uzan
- Sentinel lymph nodes: when is it contraindicated? Catherine Uzan
- Immediate reconstruction: to whom not to propose it? Isabelle Sarfati, Anne Sabaila
- 09.45-10.30 AM: THE CHALLENGES OF BREAST CANCER RADIOTHERAPY IN 2022 ROUND TABLE MODERATED BY Yazid Belkacemi
- Hypo fractionated schemes: to whom not to propose it? Sofia Rivera
- Irradiation of the internal mammary chain: who should benefit from it? Agnès Tallet
- 10:30-11:00 AM: break
- 11h00-11h45 AM: THERANOSTIC ISSUES IN THE MANAGEMENT OF BREAST CANCER IN 2022 ROUND TABLE MODERATED BY Pascal Pujol et Jean-Marc Guinebretière (TBC)
- What routine tests for the management of non-metastatic breast cancer.
 Nina Radosevic
- What routine tests for the management of metastatic breast cancer. (TBD)
- 11:45 AM to 12:30 PM: THE CHALLENGES OF THE MANAGEMENT OF HR POSITIVE BREAST CANCERS IN 2022 ROUND TABLE MODERATED BY Paul Cottu
- Chemotherapy de-escalation in adjuvant setting: for whom? Marc-Antoine Benderra
- Antihormonal treatment escalation in an adjuvant setting: how? Johanna Wassermann

≥12:30-1:30 PM

LUNCH-DEBATE

With the Support of ASTRAZENECA/DAIICHI SANKYO

Round table: Paradigm shift in the management of breast cancer?

Chairperson: Olivier Tredan

Speakers: Magali Lacroix-Triki, Sylvain Ladoire

>1:30-2:00 PM

LUNCH BOX

02:00-02:30 PM

>LA LECON DES IFODS

THERAPEUTICAL INNOVATIONS: WHERE? FOR WHOM AND HOW?

Chairpersons: Jean-Jacques Zambrowski, Muriel Dahan et Jean-Philippe Metges



LA SEINE (PLENARY)

02:30-04:30 PM

▶ CONSENSUS AND GUIDELINES FOR BREAST CANCER (2)

Under the aegis of St Paul & AROME

Presidents: Moïse Namer, Marc Spielmann, Yazid Belkacemi, Joseph Gligorov

- 02:30-03:15 PM: THE CHALLENGES OF THE MANAGEMENT OF HER2 POSITIVE BREAST CANCERS IN 2022 ROUND TABLE MODERATED BY Jean-Yves Pierga
- HER2 low cancers: what to do? Edith Perez
- Which strategy in metastatic situation for HER2 positive cancers? Sandra Swain

03:15-03:30 PM: pause / visite sur les stands / break

• 03:30-04:15 PM: THE CHALLENGES OF TREATING TRIPLE-NEGATIVE BREAST CANCER IN 2022 ROUND TABLE MODERATED BY Suzette Delaloge

With the Support of MSD

- Which optimal treatment in a non-metastatic in adjuvant and neoadjuvant situation? Olivier Tredan With the Support of GILEAD
- Which optimal treatment in metastatic situation? Elise Deluche 🚇

>04:30-05:30 PM

SYMPOSIUM

With the Support of NOVARTIS

MANAGEMENT OF METASTATIC BREAST CANCER RH+ HER2-

Chairperson: Jean Philippe Spano

- · Panorama in 1st line metastatic breast cancer and beyond? Marc Antoine Benderra
- Place of cardio-oncology in the management of breast cancer. Joe Elie Salem
- · Particularities of the management of pre-menopausal women. Marie Beguinot

MISSISSIPI

09:00-12:30 PM

▶BIOTECH IN ONCOLOGY







Under the aegis of Gustave Roussy Transfert, Cancer Campus and Angels Santé

Chairperson(s): Jean-Pierre Armand (Gustave Roussy, Villejuif), Stéphane Loze (Angels Santé, Paris) 09:00-10.30 AM

PART I: "ACCELERATION" A KEY STEP FOR ONCOLOGY BIOTECHS!

- The acceleration induced by the « 2030 Innovation Plan »: the example of the Paris Saclay Cancer Cluster. Éric Vivier, President of Paris Saclay Cancer Cluster association
- The acceleration induced by Europe: the example of the EIT Health Institute (European Institute for Innovation and Technology in Health).

Jean-Marc Bourez, Interim CEO EIT Health Europe & Managing Director EIT Health France Executif member, VitaDX

10:30-11:00 AM: pause / visite sur les stands / break



• Acceleration induced by « private financing »: the example and approach of a Ventures Capital Sofinnova Partners.

Joël Yao, Sofinnova Partners

Sébastian Amigorena, PhD researcher as Curie Institute - Scientific Founder of Mnemo Therapeutics

11:00 AM-12.30 PM

PART II: "STARTUP PITCH"

- Selection of 8 projects following the call for applications startups that can be : biotech, medtech, esanté, diag, Al ... 7mn per pitch + 3mn Q&A with the public and the panel of experts
- Ultra-sensitive ctDNA detection with NGS in liquid biopsies. FLOATING GENES. Dipanwita Biswas
- Polymer drug conjugate: unlocking the full potential of highly potent anticancer drugs. IMESCIA. Tanguy Boissenot
- A Novel Bioreactor Design for Closed and Automated CAR T Cell Manufacturing. LIMULA. Luc Henry
- HolisTM GV, an innovative patient-centered digital solution that aims to transform patient care for multimorbid elderly cancer patients. MYPL. Christophe Vergne
- ORAKL Biological Avatars to treat cancer patients. ORAKL (GUSTAVE ROUSSY SPIN-OFF) . Fanny Jaulin
- · A new Biotech in onco-dermatology: from reflection to action! RIBONEXUS. Caroline Robert
- ScreenACT : Digital solutions to optimize recruitment in clinical trials. SCREENACT. Sébastien Mourey
- Fluorescent immunoconjugates to detect the invisible in real time, and reduce the severity of the surgery. VIEWAVES. Frédéric Le Moigne

≥12:30-1:30 PM

SYMPOSIUM

With the Support of BMS

IMMUNOTHERAPY IN PAN-TUMOR NEWS IN LOCALLY ADVANCED/ METASTATIC SITUATIONS

Chairpersons: Nicolas Girard

· Focus: for whom, how, what benefits,

In esophageal and gastroesophageal cancers. Emmanuelle Samalin

In urathelial cancers. Aude Fléchon

≥1:30-2:00 PM

LUNCH BOX



MISSISSIPI

02:30-04:15 PM

▶CONSENSUS AND GUIDELINES FOR ONCODERMATOLOGY

President and Chairpersons: Barouyr Baroudjian, Céleste Lebbe, Caroline Robert, Donia Lassoued and Stéphane Barete

- · Adjuvant treatment for melanoma: which one and for who? Emilie Routier
- Management of metastatic melanoma: is there a consensus? Elisa Funck-Brentano

03:15-03:30 PM: pause / visite sur les stands / break

- Discontinuation of Treatment in Responding Patients with metastatic melanoma. Ouidad Zehou
- News in non-melanoma skin cancers in immunocompromised patients (organ transplant patients). Stéphane Barete

04:15-05:15 PM

▶GYNECOLOGICAL CANCERS: "HIGHLIGHTS FROM THE SGO AND ASCO"

Under the aegis of SFCO, GINECO GROUP & SFMPP

Chaipersons: Anne-Claire Hardy-Bessard, Isabelle Ray Coquard, Pascal Pujol

- · Surgical news (or what's new in surgery?) Gwenaël Ferron, Enora Laas
- · Medical news (or what's new in surgery?) Patricia Pautier, Jérôme Alexandre
- · Diagnostic and genomic news (or what's new on molecular markers?) Pascal Pujol, Laetitia Collet

ST LAURENT

09:00-12:30 AM

▶CONSENSUS AND GUIDELINES FOR UROLOGY: PROSTATE CANCER CARE

Under the aegis of AFU

With the Support of ASTELLAS

President and Chairpersons: Thierry Lebret, Arnaud Mejean, Mathieu Minsat, Luca Campedel and Ronan Flippot

- Localized prostate cancer: active surveillance
- To which patient can we offer active surveillance? Pierre Mongiat-Artus
- What support plan? Arnaud Mejean
- · Relevance of care
- How to manage the PSA (unjustified?) after 80 years? Thierry Lebret
- What are unnecessary toe choline applications? Marc Berthaux

10:30-11:00 AM: pause/visite sur les stands/break

- <u>Update on hormone-sensitive metastatic prostate cancer</u>
- ADT+NHT. (TBD)
- Triplet: castration + Docetaxel + NHT. Charles Dariane

<u>Update on hormone-resistant prostate cancer</u>

- The extension report in 2022
- Place of chemotherapy. Luca Campedel
- Place of iPARPs and Lu-PSMA. Ronan Flippot



ST LAURENT

>12:30-1:30 PM

· LUNCH-DEBATE

With the Support of MYRIAD GENETICS

TUMOR GENOMICS AND GENETICS: INNOVATION AND IMPLEMENTATION IN FRANCE

Moderator: Jean-Philippe Spano

EndoPredict: Clinical application of a genomic test, news related to EndoPredict - Marie-

Ange Mouret

MyChoice: Mutation status research application in ovarian cancer - Benoît You

≥1:30-2:00 PM

LUNCH BOX

02:30-04:45 PM

▶INNOVATIONS IN RADIOTHERAPY

Under the aegis of SFRO & SFJRO

Presidents: David Azria, Florence Huguet and Yasmine El Houat

<u>Innovations in radiotherapy</u>

- · Auto-segmentation, MRI dosimetry, real-time influencers: present or future? Morgan Michalet
- Flash radiotherapy: electrons and protons: the first patient treated? Mahmut Ozsahin
- · Radiotherapy of refractory ventricular tachycardia: the French experience. Jonathan Khalifa

03:15-03:30 PM: pause / visite sur les stands / break

- Breast radiotherapy in 5 fractions: for whom? Sofia Rivera
- Radiotherapy of the primary tumor in a metastatic situation: standard in all indications?
 Youssef Ghannam

> POSTERS SESSION (on the Exhibition area)



FRIDAY 24th JUNE

LA SEINE (PLENARY)

09:00 AM-12.30 PM

▶ HIGHLIGHTS FITI* SESSION (International Meetings Update)

2022 A MAJOR ONCOLOGY YEAR

Presidents and Chairpersons: Charles Canova, Aurélien Gobert, Sandra Swain, Romain Cohen With the Support of STEMLINE-MENARINI FRANCE

- Update of ASCO 2022, SABCS 2021 and ESMO Breast 2022 for Breast Cancer highlights. Sandra Swain
 With the Support of PFIZER
- RH+/HER2- in a metastatic situation: recommendations in 2022. Jean-Yves Pierga
- · Best of 2022: thoracic oncology and Radiation therapy. Charles Canova

10:30-11:00 AM: pause / visite sur les stands / break

- · Higlights in GI oncology. Romain Cohen
- Best of 2022 in Urology. Aurélien Gobert
- · Focus on MSI tumors. Thierry André

>12:30-1:30 PM

LUNCH-DEBATE

Under the aegis of ST PAUL & AROME With the Support of SEAGEN

EUROPEAN GUIDELINES FOR BREAST CANCER

Chairpersons: Joseph Gligorov et Jean-Philippe Spano

Speaker: Giuseppe Curigliano

≥1:30-2:00 PM

LUNCH BOX

MISSISSIPI

09:00-12:30 AM

CONSENSUS AND GUIDELINES FOR GI TUMORS

Under the aegis of Prodige Group, UNICANCER GI, GERCOR, FFCD With the Support of MSD

Chairpersons: Thomas Aparicio & Christelle de la Fouchardière

- · Advantage of determining circulating tumor DNA. Frédéric Di Fiore
- Which targeted therapies in the treatment of cholangiocarcinomas? David Malka (TBC)
- Management of primary and secondary tumors of the peritoneum. Diane Goere

10:30-11:00 AM: pause / visite sur les stands / break

Chairpersons: Christophe Louvet & Emmanuelle Samalin

- · How to treat locally advanced pancreatic adenocarcinoma? Pascal Hammel
- Indications and "utility" of NGS phenotyping of digestive tumors. Emmanuelle Samalin
- · Diagnosis and treatment of HER2 digestive tumors? Romain Cohen

>1:30-2:00 PM

LUNCH BOX

ST LAURENT

09:00-10:30 AM

▶CANCER, APRÉS-CANCER, RESSOURCES ET RÉSILIENCE

Sous l'égide d'Europa Donna, Life is Rose, L'UDP, Patients en réseau



FRIDAY 24th JUNE

President and Chairperson: Jean-Jacques Zambrowski,

Speakers: Nathalie Savariaud, Maryline Baranes, Gary Rodin, Laure Guéroult-Accolas, Philippe Jeannin, Marilyne Rebillon et Brigitte Heuls

- · Le Café du Rétablissement : un exemple d'offre dans le Parcours de soins en oncologie. Maryline Rébillon
- · Rôle thérapeutique de l'Acupuncture en cancérologie. Philippe Jeannin

With the Support of The L'OREAL FONDATION

10:00 • Un nouvel outil de mesure d'impact de la socio-esthétique : Patient Centricity Questionnaire. Sylviane Balustre d'Erneville

• Référent métier études clinique en socio-esthétique GEX AFSOS. Cécile Bartoloni-Grosjean, Socio-esthéticienne spécialisée en oncologie - Centre Antoine Lacassagne et association de La Ligue contre le cancer - Nice

10:30-11:00 AM: pause / visite sur les stands / break

11:00-12:30 AM

▶ CONSENSUS AND GUIDELINES FOR SARCOMA

Under the agais of GSF - GETO & NET- SARC

Chairperson(s): Axel Le Cesne, Jean-Yves Blay and Aurore Vozy SARCOMA

- Reference center and sarcoma. François Gouin
- · What's up for Gist treatment. Axel Le Cesne
- Cellular therapy for sarcoma treatment. (TBD)
- Molecular medicine of cancer: ongoing actions and challenges. Is more better? Profiler 2: a randomized trial testing 2 different panel sizes. Medhi Brahmi

PERSONALIZED MEDICINE

- The Multisarc protocol, Antoine Italiano
- High throughput sequencing platform for somatic alterations of cancer: the organization & first results. Pierre Saintigny
- Protocol Acse 2.0 for rare molecular alterations (TBD)
- New agents in routine or close to routine use. Christophe Massard

≥1:30-2:00 PM

LUNCH BOX

02:00-03:30 PM

▶HEART VESSELS AND CANCERS

Chairperson(s): Joe-Elie Salem, Francis Cajfinger and Corinne Frere

- · Cancer and cardiac metastasis: how to make the diagnosis? Stéphane Ederhy
- AF and cancer: what management? Joachim Alexandre 🚇
- Direct oral anticoagulant for the treatment of cancer-associated thrombosis: an update. Corinne Frère

NEWS/EXPERT OPINION

With the Support of LEO PHARMA

• What are the prerequisites to know or avoid before setting up an anticoagulant treatment in patients with cancer and thrombosis? Audrey Bellesoeur

03:30-04:00 PM

POSTERS AWARD





Abstracts Submission **Deadline: May 10th, 2022**

SUBMISSION GUIDELINES

- Abstracts have to be submitted electronically and in English
- Abstracts received after the deadline (May 10th, 2022) will not be considered
- Supply as much information as possible: the precise subject of study, methods used where appropriate, summary of results obtained, conclusion
- As it is assumed that original work will be presented, no bibliographic references are necessary
- Selected **abstracts** will be published in the abstract book exactly as you submitted it. Therefore, proofreading is essential, no modification will be possible after submission.
- Your **abstract** should not contain accents or any other invalid character, which would not be part of the English alphabet.
- Your **abstract's** text should not exceed 3,000 characters (excluding spaces)
- The main author (presenter) confirms that all authors are aware of and agree to the content of the abstract and support of the data presented. By submitting his abstract, the author allows the IFODS to publish and distribute or sell his abstract as part of the Abstract Book, which may be distributed on paper.
- All selected **abstracts** will be published in the abstract book. Papers accepted for IPOSTER presentation will be displayed during poster sessions.
- Acceptance or rejection of the paper by the Scientific Committee will be notified by email to the main author (presenter) by May 14^{th} , 2022
- Only persons whose registration is complete will be able to present their abstracts
- IPOSTERS will be awarded or encouraged: a special jury will select the three best posters and their authors will receive IFODS Poster Award and a cheque of 500€ each.

Registration (Allows to access all satellite meetings of the IFODS)				
REGISTRATION FEES (in Euros)	Regular Registration			
From Dec. 15 th 2021 to Feb. 15 th 2022	□ 500 € HT			
From Feb 16 th 2022 and on site	□ 600 € HT			
Student registration fees ☐ 100 € HT (The participation of student is conditioned by the full coverage of their hospitality costs)				

WAY OF REGISTRATION

Online Registration: secure online registration and payment by credit card via the website **www.ifods.com** Registration will be validated only with payment by credit card (Visa, Mastercard). Registration Form sent by Fax or Mail:

you can download the registration form on the website and send it duly completed to the Organisation Committee. Registration will be validated only with payment attached or credit card information completed. Cancellation Policy / Before May 10th, 2022: 50% cancellation fees / From May 11th, 2022: no refund



International Medical Events (IME)
38 rue de Laborde - 75008 Paris- France - Email: infos@im-events.com
Organisation Committee

Contact : Valérie CAILLON : Tel : + 33 1 41 04 04 35 - Fax : +33 1 41 04 04 11 Email: valerie.caillon@im-events.com
Travel Information & Accommodation

Contact : Mathilde MANGIN : Tel : + 33 1 41 04 04 31 - Fax : +33 1 41 04 04 11

Email: mathilde.mangin@im-events.com

CONGRESS LOCATION RIVE MONTPARNASSE

LOCALISATION **ET ACCÈS**

44 Boulevard de Vaugirard, Paris 15°




Lignes 4, 6, 12 et 13 (Montparnasse, Gaitée)

Lignes n° 28, 58, 91, 92, 94, 95, 96,88

PARKING

Parking Pasteur Interparking





I.M.E, la marque P.C.O du Groupe Equatour

Infos@im-events.com Tel.: 00 33 (0)1 41 04 04 04 / Fax: 00 33 (0) 1 41 04 04 11



WITH SKYTEAM, YOUR GLOBAL MEETING IS SIMPLE TO ORGANISE AND EVEN EASIER TO GET TO.

Whether you are the organiser or the participant, the Global Meetings Program allows you to benefit from the expertise of SkyTeam's network covering over 1,000 destinations worldwide. Via the online portal, not only can participants obtain discounted travel, but fl ights and connections are made more convenient. Organisers can also take advantage of an online solution especially designed to meet their needs, including a productivity reward program. Additionally, we provide you with a communications kit and one point of contact to help manage your event. Visit our website www.skyteam.com/globalmeetings























AIR FARE DISCOUNT - Event ID: 38 168 AF

SkyTeam Global Meetings Agreement - This Agreement is entered into by and among member airlines of the SkyTeam Alliance and EQUATOUR. The airlines of SKYTEAM, Official Alliance Network for the IFODS 2022, offer attractive airfares for participants. SKYTEAM comprises 19 leading international airlines serving 1000 destinations in 187 countries with over 15 000 flights daily.

GLOBAL MEETINGS PROGRAM - TICKETS PURCHASING

The Discount Agreement will be for travel between June 15th throught July 1st 2022. To benefit from these special offers, link up with http://globalmeetings.skyteam.com and quote the Identifier Code 38 168 AF Tickets purchased on the following Carriers are eligible for the SkyTeam Global Meetings programme:

Aeroflot, Aerolíneas Argentinas, Aeroméxico, Air Europa, Air France, Alitalia, China Airlines, China Eastern, China Southern, Czech Airlines, Delta Air Lines, Kenya Airways, KLM Royal Dutch Airlines, Korean Air, Middle East Airlines, Saudia, TAROM, Vietnam Airlines and Xiamen Air.

To book your travel now, visit www.skyteam.com/GlobalMeetings and enter your Event ID, 38 168 AF

Through this site you can also access the schedules of all SkyTeam partners to plan your flights on the airline of your choice.



International Medical Events - IME spécialiste de la gestion de congrès médicaux





IME, la marque P.C.O du Groupe Equatour

